DCPH — Deciphera Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.21bn
- $1.94bn
- $163.36m
- 77
- 10
- 84
- 58
Annual income statement for Deciphera Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 25 | 42.1 | 96.1 | 134 | 163 |
| Cost of Revenue | |||||
| Gross Profit | — | 41.9 | 93.2 | 125 | 160 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 226 | 313 | 396 | 317 | 374 |
| Operating Profit | -201 | -271 | -300 | -183 | -211 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -192 | -266 | -300 | -178 | -195 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -192 | -266 | -300 | -179 | -195 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -192 | -266 | -300 | -179 | -195 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -192 | -266 | -300 | -179 | -195 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.48 | -4.78 | -5.16 | -2.37 | -2.29 |